Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Oncologist
    September 2025
  1. CHEN G, Zhu J, Jian C, Chen X, et al
    Efficacy and safety of Rh-endostatin in the treatment of radiation pneumonitis in non-small cell lung cancer.
    Oncologist. 2025 Sep 27:oyaf318. doi: 10.1093.
    >> Share

  2. LIU Y, Li X, Zhang M, Gao Y, et al
    A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small cell lung cancer.
    Oncologist. 2025 Sep 25:oyaf306. doi: 10.1093.
    >> Share

  3. LIANG J, Waliany S, Do A, Peterson JL, et al
    ENIGMA+: a national, decentralized, remote consent study for clinical data and biospecimen collection in patients with ALK-positive advanced NSCLC.
    Oncologist. 2025;30:oyaf217.
    >> Share

  4. LI X, Gong W, Yao X, Gao Y, et al
    Effects of magnesium concentration on the regulation of nutrition and inflammation in nutritional support for cancer patients.
    Oncologist. 2025;30:oyaf211.
    >> Share

  5. LIU Y, Liu F, Wang C, Yan Y, et al
    Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis.
    Oncologist. 2025;30:oyaf266.
    >> Share

  6. LISBERG A, Huppert LA, Halmos B, Ledezma B, et al
    Datopotamab deruxtecan-associated select adverse events: clinical practices and institutional protocols on prophylaxis, monitoring, and management.
    Oncologist. 2025;30:oyaf225.
    >> Share

    August 2025
  7. WANG J, Sajeev G, Chai X, Takundwa R, et al
    Efficacy Outcomes Between Tarlatamab and Real-World Physicians' Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung Cancer.
    Oncologist. 2025 Aug 21:oyaf256. doi: 10.1093.
    >> Share

  8. VELCHETI V, Sun X, Hanna M, Zimmerman NM, et al
    Predictors of outcomes in advanced non-small cell lung cancer treated with pembrolizumab maintenance.
    Oncologist. 2025;30:oyaf070.
    >> Share

  9. CHAE YK, Oh Y, Kim L, Park JH, et al
    Bilateral orthotopic lung transplantation for the patient with lung-limited invasive mucinous adenocarcinoma: a case-based literature review.
    Oncologist. 2025;30:oyae263.
    >> Share

    July 2025
  10. WANG L, Gao M, Wang T, Cui P, et al
    First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study.
    Oncologist. 2025;30:oyaf155.
    >> Share

  11. ZHOU C, Huang R, Yuan Y, Schnell P, et al
    Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.
    Oncologist. 2025;30:oyaf177.
    >> Share

  12. FLOREZ N, LeBoeuf NR, Rotow J, Marks JA, et al
    Mitigation and management of adverse events associated with amivantamab therapy.
    Oncologist. 2025;30:oyaf194.
    >> Share

  13. TM A, Raj L, Nair P, Vincent A, et al
    Utility And Real-World Clinical Outcomes Of Next-Generation Sequencing In Advanced Non-Small-Cell Lung Cancer In South Indian Population.
    Oncologist. 2025 Jul 1:oyaf168. doi: 10.1093.
    >> Share

    June 2025
  14. ISAWA T, Togashi S, Taguri M, Toi Y, et al
    Cardiovascular adverse events in patients with lung cancer treated with immune checkpoint inhibitors: a nationwide database study.
    Oncologist. 2025;30:oyaf151.
    >> Share

  15. WANG W, Xu X, Liu H, Cui Y, et al
    The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.
    Oncologist. 2025;30:oyaf114.
    >> Share

  16. LI G, Greene SB, Kaur B, Keller-Evans RB, et al
    Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer.
    Oncologist. 2025;30:oyaf159.
    >> Share

  17. FRISCH A, Martin E, Kim SY, Riess JW, et al
    KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.
    Oncologist. 2025;30:oyaf153.
    >> Share

    May 2025
  18. GIRARD N, Xu Q, Camidge DR, Baijal S, et al
    Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101.
    Oncologist. 2025;30:oyaf029.
    >> Share

  19. LIN VTG, Ma E, Jain N, Xia Z, et al
    A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.
    Oncologist. 2025;30:oyaf067.
    >> Share

  20. XING P, Pu X, Zhou Y, Liu Z, et al
    Efficacy and safety of dacomitinib in treatment-naive patients with advanced NSCLC and brain metastasis: a multicenter cohort study.
    Oncologist. 2025;30:oyaf079.
    >> Share

  21. HU X, Melson JW, Pan SS, Salei YV, et al
    Palliative and end-of-life care in Asian and White patients with metastatic lung cancer.
    Oncologist. 2025;30:oyaf065.
    >> Share

    April 2025
  22. BAUTISTA-GONZALEZ E, Munoz Rocha TV, Soto-Perez-de-Celis E, Vindrola-Padros C, et al
    Treatment delays in patients with lung cancer: a retrospective study conducted at the National Cancer Institute of Mexico between 2004 and 2021.
    Oncologist. 2025;30:oyae358.
    >> Share

    March 2025
  23. PENAULT-LLORCA F, Socinski MA
    Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.
    Oncologist. 2025 Mar 24:oyae357. doi: 10.1093.
    >> Share

  24. LEVI A, Blais E, Davelaar J, Ebia MI, et al
    Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database.
    Oncologist. 2025;30:oyaf007.
    >> Share

  25. GRAY Z, Levonyak N, Jia L, Ahn R, et al
    Managing elderly patients with dual metastatic cancers-navigating diagnostic and treatment challenges.
    Oncologist. 2025;30:oyaf026.
    >> Share

  26. VITALE A, Vita E, Stefani A, Cancellieri A, et al
    Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.
    Oncologist. 2025;30:oyaf030.
    >> Share

  27. LI Y, Li C, Zhao X, Li Y, et al
    Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial.
    Oncologist. 2025;30:oyae336.
    >> Share

  28. VON ITZSTEIN MS, Rashdan S, Dahlberg SE, Gerber DE, et al
    Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancer.
    Oncologist. 2025;30:oyaf036.
    >> Share

  29. RADWAN A, Jani CT, Al Omari O, Patel M, et al
    The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients.
    Oncologist. 2025;30:oyae279.
    >> Share

    February 2025
  30. LEITE DA SILVA LF, Saldanha EF, de Menezes JSA, Halamy Pereira L, et al
    Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Oncologist. 2025;30:oyae344.
    >> Share

  31. SALDANHA EF, Cordeiro de Lima VC, Fares A, Corassa M, et al
    Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP).
    Oncologist. 2025;30:oyae347.
    >> Share

  32. RESTIVO L, Rochigneux P, Bouhnik AD, Arciszewski T, et al
    Patients' psychosocial attributes and aggressiveness of cancer treatments near the end of life.
    Oncologist. 2025;30:oyae317.
    >> Share

    January 2025
  33. SKOULIDIS F, Li BT, Hochmair M, Govindan R, et al
    Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.
    Oncologist. 2025;30:oyae356.
    >> Share

  34. ARNDT A, Neumann C, Riecke A, Bauer A, et al
    Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma.
    Oncologist. 2025;30:oyae143.
    >> Share

    December 2024
  35. MEHLMAN C, Swalduz A, Monnet I, Morin C, et al
    COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.
    Oncologist. 2024 Dec 26:oyae312. doi: 10.1093.
    >> Share

  36. CHEN LN, Ma X, Herzberg B, Henick BS, et al
    Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer.
    Oncologist. 2024 Dec 19:oyae315. doi: 10.1093.
    >> Share

  37. LEE HJ JR, Boscardin J, Walter LC, Smith AK, et al
    Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
    Oncologist. 2024 Dec 9:oyae349. doi: 10.1093.
    >> Share

    November 2024
  38. NAIDOO J, Johnson DB, Doran C, Wang Y, et al
    Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors.
    Oncologist. 2024 Nov 20:oyae318. doi: 10.1093.
    >> Share

  39. SADAGOPAN N, Komlodi-Pasztor E, Veytsman I
    Immunotherapy benefits for large brain metastases in non-small cell lung cancer.
    Oncologist. 2024 Nov 15:oyae314. doi: 10.1093.
    >> Share

    October 2024
  40. ARRIETA O, Ramos-Ramirez M, Garces-Flores H, Cabrera-Miranda LA, et al
    Evaluation of a risk-sharing agreement for atezolizumab treatment in patients with non-small cell lung cancer: a strategy to improve access in low-income countries.
    Oncologist. 2024 Oct 19:oyae272. doi: 10.1093.
    >> Share

  41. CAVAGNA RO, Escremim de Paula F, Berardinelli GN, Bonatelli M, et al
    Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies.
    Oncologist. 2024;29:e1419-e1424.
    >> Share

    September 2024
  42. SHAW J, Pundole X, Balasubramanian A, Anderson ES, et al
    Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.
    Oncologist. 2024 Sep 30:oyae234. doi: 10.1093.
    >> Share

  43. APTER L, Sharman Moser S, Gazit S, Chodick G, et al
    Healthcare resource utilization and associated cost in patients with metastatic non-small cell lung cancer treated in the immunotherapy era.
    Oncologist. 2024 Sep 28:oyae240. doi: 10.1093.
    >> Share

  44. SEBASTIAN NT, Stokes WA, Behera M, Jiang R, et al
    The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Oncologist. 2024 Sep 25:oyae262. doi: 10.1093.
    >> Share


  45. Correction to: Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.
    Oncologist. 2024 Sep 24:oyae253. doi: 10.1093.
    >> Share

  46. ALVES DE SOUZA G, Dornellas DMS, Campregher PV, Teixeira CHA, et al
    Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report.
    Oncologist. 2024;29:764-767.
    >> Share

  47. FLOREZ N, Patel SP, Wakelee H, Bazhenova L, et al
    Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
    Oncologist. 2024 Sep 5:oyae228. doi: 10.1093.
    >> Share

    August 2024
  48. DHAWALE TM, Bhat RS, Johnson PC, Srikonda S, et al
    Telemedicine-based serious illness conversations, healthcare utilization, and end of life care among patients with advanced lung cancer.
    Oncologist. 2024 Aug 29:oyae216. doi: 10.1093.
    >> Share

  49. BOULANGER MC, Schneider JL, Lin JJ
    Advances and future directions in ROS1 fusion-positive lung cancer.
    Oncologist. 2024 Aug 23:oyae205. doi: 10.1093.
    >> Share

  50. MACK PC, Keller-Evans RB, Li G, Lofgren KT, et al
    Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC.
    Oncologist. 2024;29:e984-e996.
    >> Share

    July 2024
  51. FALADE A, Zubiri L, Wu CY, Perlman K, et al
    Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights.
    Oncologist. 2024 Jul 26:oyae189. doi: 10.1093.
    >> Share

  52. MEYER ML, Hirsch FR, Bunn PA, Ujhazy P, et al
    Calls to action on lung cancer management and research.
    Oncologist. 2024 Jul 13:oyae169. doi: 10.1093.
    >> Share

  53. MEHTA GU, Vellanki PJ, Ren Y, Amatya AK, et al
    FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
    Oncologist. 2024 Jul 6:oyae151. doi: 10.1093.
    >> Share

  54. CHANG AEB, Piper-Vallillo AJ, Mak RH, Lanuti M, et al
    The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
    Oncologist. 2024;29:609-618.
    >> Share

  55. CHENG W, Xu T, Yang L, Yan N, et al
    Dramatic response to crizotinib through MET phosphorylation inhibition in rare TFG-MET fusion advanced squamous cell lung cancer.
    Oncologist. 2024 Jul 2:oyae166. doi: 10.1093.
    >> Share

    June 2024
  56. JAYAKRISHNAN R, Kwiatkowski DJ, Rose MG, Nassar AH, et al
    Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations.
    Oncologist. 2024 Jun 22:oyae091. doi: 10.1093.
    >> Share

  57. NEAL JW, Minichiello K, Brennick R, Huang RSP, et al
    A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
    Oncologist. 2024;29:e843-e847.
    >> Share

    May 2024
  58. VALLEJO J, Singh H, Larkins E, Drezner N, et al
    Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
    Oncologist. 2024;29:422-430.
    >> Share

    April 2024
  59. CHEN HW, Kuo YW, Chen CY, Chang CH, et al
    Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.
    Oncologist. 2024;29:e498-e506.
    >> Share

  60. ARRIOLA E, Jaal J, Edvardsen A, Silvoniemi M, et al
    Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.
    Oncologist. 2024;29:e561-e569.
    >> Share

  61. ALLENDE S, Turcott JG, Verastegui E, Rodriguez-Mayoral O, et al
    Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial.
    Oncologist. 2024 Apr 1:oyae050. doi: 10.1093.
    >> Share

    March 2024
  62. XU Y, Ji H, Zhang Y, Xiong L, et al
    Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2024 Mar 25:oyae052. doi: 10.1093.
    >> Share

  63. PASELLO G, Lorenzi M, Scattolin D, Del Conte A, et al
    Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
    Oncologist. 2024 Mar 23:oyae043. doi: 10.1093.
    >> Share

  64. XU Y, Wen N, Haddad RI, Sonis ST, et al
    Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
    Oncologist. 2024;29:e382-e391.
    >> Share

    February 2024
  65. STRICKER T, Jain N, Ma E, Yu E, et al
    Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
    Oncologist. 2024 Feb 28:oyae022. doi: 10.1093.
    >> Share

  66. BRIA E, Morgillo F, Garassino MC, Ciardiello F, et al
    Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
    Oncologist. 2024 Feb 20:oyad342. doi: 10.1093.
    >> Share

    January 2024
  67. KATAYAMA Y, Yamada T, Sawada R, Kawachi H, et al
    Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
    Oncologist. 2024 Jan 18:oyae001. doi: 10.1093.
    >> Share

  68. GERBER DE, Wang Y, Ramalingam SS, Bhalla S, et al
    Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
    Oncologist. 2024 Jan 11:oyad335. doi: 10.1093.
    >> Share

  69. WANG H, Fan Z, Yang X, Wu Q, et al
    Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-small Cell Lung Cancer: A Case Report.
    Oncologist. 2024 Jan 10:oyad339. doi: 10.1093.
    >> Share

  70. BONANNO L, Lorenzi M, Massa D, De Nuzzo M, et al
    Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting.
    Oncologist. 2024;29:e118-e130.
    >> Share

  71. HORIUCHI K, Ikemura S, Sato T, Shimozaki K, et al
    Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.
    Oncologist. 2024;29:e108-e117.
    >> Share

  72. JORDAN J, Maki RG
    The Weighted Toxicity Score: Confirmation of a Simple Metric to Communicate Toxicity in Randomized Trials of Systemic Cancer Therapy.
    Oncologist. 2024;29:67-74.
    >> Share

    November 2023

  73. Correction to: Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Oncologist. 2023 Nov 24:oyad316. doi: 10.1093.
    >> Share

  74. STRICKLER JH, Yoshino T, Stevinson K, Eichinger CS, et al
    Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.
    Oncologist. 2023;28:e981-e994.
    >> Share

    October 2023
  75. HU X, Melson JW, Pan SS, Salei YV, et al
    Screening, Diagnosis, and Initial Care of Asian and White Patients With Lung Cancer.
    Oncologist. 2023 Oct 5:oyad272. doi: 10.1093.
    >> Share

  76. SILVERSTEIN J, Wright F, Wang M, Young A, et al
    Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors.
    Oncologist. 2023;28:e950-e959.
    >> Share

    September 2023
  77. SHANG X, Zhang C, Kong R, Zhao C, et al
    Construction of a Diagnostic Model for Small Cell Lung Cancer Combining Metabolomics and Integrated Machine Learning.
    Oncologist. 2023 Sep 14:oyad261. doi: 10.1093.
    >> Share

  78. HASEGAWA T, Okuyama T, Uemura T, Matsuda Y, et al
    Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer.
    Oncologist. 2023 Sep 5:oyad245. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016